Modality
ERT
MOA
PRMT5i
Target
Nectin-4
Pathway
Ferroptosis
Breast Ca
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Oct 2030
NDA/BLACurrent
NCT03556704
856 pts·Breast Ca
2022-03→2030-10·Active
856 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-224.6y awayPh3 Readout· Breast Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-10-22 · 4.6y away
Breast Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03556704 | NDA/BLA | Breast Ca | Active | 856 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |